FDA poised to approve $5 MILLION gene therapy to treat muscular atrophy
The FDA is expected to approve Zolgensma, the world's second gene therapy for spinal muscular atrophy. Expert's worry that the two drugs for the disease are setting an expensive precedent.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news